DROMOSTANOLONE PROPIONATE


Trade Names	DROLBAN
Synonyms	32379 Drolban Dromostanolone Dromostanolone propionate Drostanolone Drostanolone propionate Masterid Masteril Masteron NSC-12198 NSC-1298 Permastril
Status
Molecule Category	UNKNOWN
UNII	X20UZ57G4O
EPA CompTox	DTXSID1022972


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	NOTIQUSPUUHHEH-UXOVVSIBSA-N
Smiles	CCC(=O)O[C@H]1CC[C@H]2[C@@H]3CC[C@H]4CC(=O)[C@H](C)C[C@]4(C)[C@H]3CC[C@]12C
InChI	InChI=1S/C23H36O3/c1-5-21(25)26-20-9-8-17-16-7-6-15-12-19(24)14(2)13-23(15,4)18(16)10-11-22(17,20)3/h14-18,20H,5-13H2,1-4H3/t14-,15+,16+,17+,18+,20+,22+,23+/m1/s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C23H36O3
Molecular Weight	360.54
AlogP	5.17
Hydrogen Bond Acceptor	3.0
Hydrogen Bond Donor	0.0
Number of Rotational Bond	2.0
Polar Surface Area	43.37
Molecular species	NEUTRAL
Aromatic Rings	0.0
Heavy Atoms	26.0

Pharmacology

Mechanism of Action	Action	Reference
Androgen Receptor agonist	AGONIST	PubMed PubMed


Protein: Androgen Receptor Description: Androgen receptor Organism : Homo sapiens P10275 ENSG00000169083

Related Entries

Cross References

Resources	Reference
ChEBI	31523
ChEMBL	CHEMBL1201048
DrugBank	DB14655
DrugCentral	965
FDA SRS	X20UZ57G4O
Guide to Pharmacology	6947
PharmGKB	PA164760855
PubChem	224004
SureChEMBL	SCHEMBL3173
ZINC	ZINC000004213057

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).